A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

Phase 4

Not yet recruiting

• Conditions: Systemic Lupus Erythematosus (SLE); Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
• Interventions: Drug: BMS-986165

• Registration Number: NCT06875960
• Lead Sponsor: Bristol-Myers Squibb

Brief Summary

The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-03
• Study First Submitted: 2025-03-12
• Study First Submitted QC: 2025-03-12
• Last Update Submitted: 2025-03-12
• Study First Posted: 2025-03-14
• Last Update Posted: 2025-03-14
• Study Start: 2025-03-17
• Primary Completion: 2026-12-01
• Study Completion: 2026-12-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Administration of BMS-986165	BMS-986165	-

Primary Outcome Measures

Name	Time	Method
Number of participants treated with BMS-986165	Up to 2 years

Trial Locations

Locations (3)

Local Institution - 0001; 🇺🇸 Farmington, Connecticut, United States

Local Institution - 0002; 🇺🇸 New York, New York, United States

Local Institution - 0003; 🇺🇸 Jackson, Tennessee, United States